Home Clinical Trials
Human Microbiota Transfer Therapy for Depression (The “Moving Moods Pilot Study”)

The dataset assesses the feasibility and safety of fecal microbiota transplant (FMT) as an adjunctive treatment for major depressive disorder (MDD) in adults. Primary outcomes focus on feasibility measures, such as participant recruitment, adherence, and retention, alongside safety through adverse event tracking. Secondary outcomes evaluate shifts in gut microbiota composition (engraftment) and mental health symptoms using the Montgomery-Asberg Depression Rating Scale (MADRS) and Depression-Anxiety Stress Scale (DASS) at multiple timepoints. Additional variables capture quality of life (AQoL-8D), functional impairment (Sheehan Disability Scale), and physiological parameters like gut symptomatology (GSRS), inflammation markers, sleep quality (PSQI), and blood biomarkers. The dataset also includes cost-effectiveness data, comparing health sector and societal costs to analyze the economic impact of FMT in conjunction with traditional depression treatments.

Subjects
Depression / Mental Health
Date made available
TBD
Data set type
Study Protocol and Statistical Analysis Plan, no IPD.
ANZCTR reference number
Publication
Green JE, Berk M, Mohebbi M, et al. Feasibility, Acceptability, and Safety of Faecal Microbiota Transplantation in the Treatment of Major Depressive Disorder: A Pilot Randomized Controlled Trial. The Canadian Journal of Psychiatry. 2023;68(5):315-326. doi:10.1177/07067437221150508
Share